Compounds > clorindione
Page last updated: 2024-12-06

clorindione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Clorindione is a synthetic anticoagulant drug that is a derivative of indandione. It acts by inhibiting the production of vitamin K-dependent clotting factors in the liver. Clorindione is used to prevent and treat venous thromboembolism (blood clots in the veins). It is also used to treat atrial fibrillation, a type of irregular heartbeat. Clorindione is available as a tablet and is typically taken by mouth. It is important to take clorindione exactly as prescribed by your doctor. It is important to note that clorindione can cause serious side effects, including bleeding. Therefore, it is important to talk to your doctor about the risks and benefits of taking clorindione. Clorindione is studied because it is an effective anticoagulant drug that has been shown to be safe and effective in treating a variety of conditions. The study of clorindione is ongoing in order to better understand its mechanisms of action and to develop new and improved anticoagulant drugs.'

clorindione: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID70846
CHEMBL ID278519
CHEBI ID135057
SCHEMBL ID43305
MeSH IDM0045809

Synonyms (81)

Synonym
einecs 214-553-2
brn 2052412
2-(p-chlorophenyl)-1,3-indandione
clorindione
clorindiona [inn-spanish]
m.g. 2552
clorindionum [inn-latin]
2-(4-chlorofenil)-1,3-indandione [italian]
g 25766
2-(4-chlorophenyl)-1h-indene-1,3(2h)-dione
indaliton
2-(4-chlorophenyl)indan-1,3-dione
chlor-athrombon
chlorindionum
clorindione [inn:ban]
chlophenadione
1,3-indandione, 2-(p-chlorophenyl)-
2-(p-chlorophenyl)indan-1,3-dione
D07135
g-25766
clorindione (inn)
1146-99-2
OPREA1_416030
NCGC00160557-01
MAYBRIDGE1_006726
MLS001249425
smr000718655
CHEBI:135057
MLS001249496
chlorphenylindandione
nsc-758878
chlorphenindione
CHEMBL278519 ,
2-(p-chlorophenyl)-1,3-indandion
AKOS001483191
HMS560J16
2-(4-chlorophenyl)indene-1,3-dione
2-(4-chloro-phenyl)-indan-1,3-dione
bdbm50280162
2-(4-chlorophenyl)-2,3-dihydro-1h-indene-1,3-dione
HMS3264O05
tox21_111897
dtxcid8026228
cas-1146-99-2
dtxsid0046228 ,
2-(4-chlorophenyl)indane-1,3-dione
HMS2980P03
nsc758878
pharmakon1600-01504507
CCG-103156
2-(4-chlorofenil)-1,3-indandione
ci-pid
unii-541c7ws64r
clorindiona
clorindionum
541c7ws64r ,
nsc 758878
mg 2552
clorindione [who-dd]
clorindione [mi]
clorindione [inn]
chlorindione
MLS006011653
SCHEMBL43305
2-(4-chlorophenyl)-1,3-indanedione
HY-B0918
AB00871292_07
chlophenadione;indaliton;g-25766
1h-indene-1,3(2h)-dione, 2-(4-chlorophenyl)-
mfcd00239203
sr-01000802967
SR-01000802967-2
DB13275
Q2358705
BRD-K61802864-001-04-7
clorindione 100 microg/ml in acetonitrile
F85192
MS-23615
S5668
2-(4'-chloropheny)lindan-1,3-dione
SY347803

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
cyclic ketone
indanones
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency31.62285.623417.292931.6228AID485281
LuciferasePhotinus pyralis (common eastern firefly)Potency28.06540.007215.758889.3584AID588342; AID624030
ATAD5 protein, partialHomo sapiens (human)Potency18.34890.004110.890331.5287AID504467
AR proteinHomo sapiens (human)Potency7.37530.000221.22318,912.5098AID743036; AID743053
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency11.22020.28189.721235.4813AID2326
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.84690.000229.305416,493.5996AID743069; AID743075
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency50.11870.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency23.91530.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency16.78550.000723.06741,258.9301AID743085
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency32.64270.00419.984825.9290AID504444
ras-related protein Rab-9AHomo sapiens (human)Potency3.16230.00022.621531.4954AID485297
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency31.62280.00419.962528.1838AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1136511Uncoupling activity of oxidative phosphorylation in rat liver mitochondria1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
A manual method for applying the Hansch approach to drug design.
AID109864Hypolipidemic activity in CF1 male mice at a dose of 20 mg/kg per day, serum triglyceride measured on the 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID109861Hypolipidemic activity in CF1 male mice at a dose of 20 mg/kg per day, serum cholesterol measured on the 16th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID109863Hypolipidemic activity in CF1 male mice at a dose of 20 mg/kg per day, serum cholesterol measured on the 9th day1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (27.27)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's5 (45.45)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.34 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
anisindione
anisindione: structure. anisindione : A cyclic beta-diketone consisting of indane-1,3-dione having a 4-methoxyphenyl substituent at the 4-position.		2.3620aromatic ketone;
beta-diketone		anticoagulant;
vitamin K antagonist
benzamide
benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides.		1.9510benzamides
clofibrate
angiokapsul: contains clofibrate & insoitolnicotinate		1.9610aromatic ether;
ethyl ester;
monochlorobenzenes		anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist
amphetamine
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.		1.9510primary amine
p-chloroamphetamine
p-Chloroamphetamine: Chlorinated analog of AMPHETAMINE. Potent neurotoxin that causes release and eventually depletion of serotonin in the CNS. It is used as a research tool.		1.9510
phenindione
Phenindione: An indandione that has been used as an anticoagulant. Phenindione has actions similar to WARFARIN, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)		2.3620aromatic ketone;
beta-diketone		anticoagulant
sulfabenzamide
sulfabenzamide : A sulfonamide containing a benzamido substituent on nitrogen. An antibacterial/antimicrobial, it is often used in conjunction with sulfathiazole and sulfacetamide as a topical, intravaginal antibacterial preparation.		1.9510benzenes;
sulfonamide antibiotic;
sulfonamide		antibacterial drug;
antimicrobial drug
4-toluenesulfonamide
4-toluenesulfonamide: RN given refers to parent cpd. toluene-4-sulfonamide : A sulfonamide that is benzenesulfonamide bearing a methyl group at position 4.		1.9510sulfonamide
benzenesulfonamide
[no description available]		1.9510sulfonamide
1,3-indandione
1,3-indandione : A member of the class of indanones that is indane in which the hydrogens at positions 2 and 4 have been replaced by oxo groups.		1.9610aromatic ketone;
beta-diketone;
indanones
bromindione
bromindione: structure		1.9610cyclic ketone;
indanones
4-methoxyamphetamine
4-methoxyamphetamine: para-methoxy derivative to amphetamine with hallucinogenic properties; minor descriptor (75-86); on line & INDEX MEDICUS search AMPHETAMINES (75-86); RN given refers to parent compound without isomeric designation		1.9510
4-chlorobenzenesulfonamide
[no description available]		1.9510sulfonamide
4-Methoxybenzamide
[no description available]		1.9510benzamides
3,4-Dichlorobenzenesulfonamide
[no description available]		1.9510sulfonamide
9-phenylguanine
[no description available]		1.9510
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Thromboembolism
Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.		01.9410